See binimetinib on Wiktionary
Download JSON data for binimetinib meaning in All languages combined (7.8kB)
{
"etymology_templates": [
{
"args": {
"1": "prefix"
},
"expansion": "prefix",
"name": "glossary"
},
{
"args": {
"1": "suffix"
},
"expansion": "suffix",
"name": "glossary"
},
{
"args": {
"1": "en",
"2": "",
"3": "-metinib",
"alt1": "bini-",
"pos1": "a unique prefix",
"pos2": "suffix indicating an inhibitor of mitogen-activated protein kinase kinase (MEK)"
},
"expansion": "bini- (a unique prefix) + -metinib (suffix indicating an inhibitor of mitogen-activated protein kinase kinase (MEK))",
"name": "affix"
}
],
"etymology_text": "From bini- (a unique prefix) + -metinib (suffix indicating an inhibitor of mitogen-activated protein kinase kinase (MEK)).",
"head_templates": [
{
"args": {
"1": "-"
},
"expansion": "binimetinib (uncountable)",
"name": "en-noun"
}
],
"hyphenation": [
"bi‧ni‧me‧ti‧nib"
],
"lang": "English",
"lang_code": "en",
"pos": "noun",
"senses": [
{
"categories": [
{
"kind": "other",
"name": "English entries with incorrect language header",
"parents": [
"Entries with incorrect language header",
"Entry maintenance"
],
"source": "w"
},
{
"kind": "other",
"name": "English entries with language name categories using raw markup",
"parents": [
"Entries with language name categories using raw markup",
"Entry maintenance"
],
"source": "w"
},
{
"kind": "other",
"name": "English terms suffixed with -metinib",
"parents": [],
"source": "w"
},
{
"kind": "other",
"name": "English terms suffixed with -tinib",
"parents": [],
"source": "w"
},
{
"kind": "topical",
"langcode": "en",
"name": "Pharmaceutical drugs",
"orig": "en:Pharmaceutical drugs",
"parents": [
"Drugs",
"Matter",
"Pharmacology",
"Chemistry",
"Nature",
"Biochemistry",
"Medicine",
"Sciences",
"All topics",
"Biology",
"Fundamental"
],
"source": "w"
}
],
"examples": [
{
"ref": "2017 February 28, Johanna C. Bendell et al., “A Phase 1 Dose-escalation and Expansion Study of Binimetinib (MEK162), a Potent and Selective Oral MEK1/2 Inhibitor”, in British Journal of Cancer, volume 116, Edinburgh: Nature Research, →DOI, →ISSN, →OCLC, page 576, column 1",
"text": "Binimetinib (MEK162; ARRY-438162) is a potent, adenosine triphosphate-uncompetitive, highly selective allosteric inhibitor of MEK1/2 with demonstrated on-target activity in vitro and in vivo, including models of cancer [...] In vivo, binimetinib displays broad anti-tumour activity in xenograft models derived from melanoma, colorectal cancer, non-small cell lung cancer (NSCLC), fibrosarcoma, cholangiocarcinoma, and pancreatic cancer. These non-clinical data support the use of binimetinib in a wide variety of tumour types, with a priority in tumours with aberrantly activated MAPK pathway signalling.",
"type": "quotation"
},
{
"ref": "2017 April 1, Reinhard Dummer et al., “Binimetinib versus Dacarbazine in Patients with Advanced NRAS-mutant Melanoma (NEMO): A Multicentre, Open-label, Randomised, Phase 3 Trial”, in David Collingridge, editor, The Lancet Oncology, volume 18, number 4, London: Lancet Publishing Group, →DOI, →ISSN, →OCLC, pages 435–445",
"text": "Binimetinib improved progression-free survival compared with dacarbazine and was tolerable. Binimetinib might represent a new treatment option for patients with NRAS-mutant melanoma after failure of immunotherapy.",
"type": "quotation"
},
{
"ref": "2018, Laurence Brunton, Bjorn Knollman, Randa Hilal-Dandan, Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 13th edition, New York, N.Y.: McGraw Hill Professional, page 1212",
"text": "Under development are binimetinib, a MEK inhibitor being studied in patients with NRAS-mutant melanoma, and encorafinib, a BRAF inhibitor being used in combination with binimetinib for patients with BRAF-mutant melanoma.",
"type": "quotation"
},
{
"ref": "2018, Shane Y. Morita et al., Textbook of General Surgical Oncology, New York, N.Y.: McGraw Hill Professional, page 187",
"text": "The initial report of the phase I/II combination trial of encorafenib and binimetinib reported on 9 BRAF inhibitor naive and 14 BRAF inhibitor pretreated patients with metastatic BRAF mutant melanoma across a range of doses.",
"type": "quotation"
},
{
"ref": "2019 July 20, Heidi Finnes, “Binimetinib (Mektovi®)”, in Oncology Times: The Newspaper for Specialists in Cancer, volume 41, number 14, Philadelphia, Pa.: Lippincott Williams & Wilkins, →DOI, →ISSN, →OCLC, page 8",
"text": "Binimetinib is an oral reversible inhibitor of mitogen-activated extracellular signal-regulated kinase (MEK) 1/2. [...] Binimetinib inhibits MEK 1/2 downstream from BRAF and halts cancer cell signaling and survival. [...] Binimetinib is approved in combination with encorafenib, a BRAF inhibitor, for the treatment of unresectable or metastatic melanoma with a BRAF V600E/K mutation, as detected by an FDA-approved test.",
"type": "quotation"
},
{
"ref": "2020, Edward Chu, Vincent T[heodore] DeVita, Jr., “Chemotherapeutic and Biologic Drugs”, in Physicians’ Cancer Chemotherapy Drug Manual 2021, Burlington, Mass.: Jones & Bartlett Learning, →ISSN, page 77",
"text": "Special Considerations [...] 7. Monitor patients for an increased risk of new primary cancers, both cutaneous and non-cutaneous, while on therapy and for up to 6 months following the last dose of binimetinib. [...] 10. Baseline and periodic CPK levels while on therapy, as rhabdomyolysis has been observed with binimetinib therapy.",
"type": "quotation"
},
{
"ref": "2020, Gail M. Wilkes, Margaret Barton-Burke, “Molecular Targeted Therapy”, in Oncology Nursing Drug Handbook 2020–2021, Burlington, Mass.: Jones & Bartlett Learning, →ISSN, page 548",
"text": "Binimetinib is given in combination with encorafenib as each drug targets a different kinase in the RAS/RAF/MEK/ERK pathway to stop malignant cell proliferation and to tell the cells to die (undergo apoptosis). [...] Terminal half-life of binimetinib is 3.5 hours. [...] No clinically significant changes in binimetinib exposure were seen in patients with severe renal impairment.",
"type": "quotation"
}
],
"glosses": [
"A drug with the molecular formula C₁₇H₁₅BrF₂N₄O₃ that inhibits mitogen-activated protein kinase kinase (MEK), and is approved for use in combination with encorafenib to treat certain melanomas."
],
"id": "en-binimetinib-en-noun-7NNo3Ysb",
"links": [
[
"pharmacology",
"pharmacology"
],
[
"drug",
"drug#Noun"
],
[
"molecular formula",
"molecular formula"
],
[
"inhibit",
"inhibit"
],
[
"mitogen-activated protein kinase kinase",
"mitogen-activated protein kinase kinase"
],
[
"MEK",
"MEK"
],
[
"approve",
"approve"
],
[
"use",
"use#Noun"
],
[
"combination",
"combination"
],
[
"encorafenib",
"encorafenib"
],
[
"treat",
"treat#Verb"
],
[
"melanoma",
"melanoma"
]
],
"raw_glosses": [
"(pharmacology) A drug with the molecular formula C₁₇H₁₅BrF₂N₄O₃ that inhibits mitogen-activated protein kinase kinase (MEK), and is approved for use in combination with encorafenib to treat certain melanomas."
],
"tags": [
"uncountable"
],
"topics": [
"medicine",
"pharmacology",
"sciences"
],
"translations": [
{
"code": "he",
"lang": "Hebrew",
"sense": "drug that inhibits mitogen-activated protein kinase kinase",
"word": "בינימטיניב"
},
{
"code": "ja",
"lang": "Japanese",
"sense": "drug that inhibits mitogen-activated protein kinase kinase",
"word": "ビニメチニブ"
},
{
"code": "sh",
"lang": "Serbo-Croatian",
"sense": "drug that inhibits mitogen-activated protein kinase kinase",
"tags": [
"Roman",
"masculine"
],
"word": "binimetinib"
}
]
}
],
"sounds": [
{
"ipa": "/bɪnɪˈmɛtɪnɪb/",
"tags": [
"Received-Pronunciation"
]
},
{
"ipa": "/bɪnɪˈmɛtɪnɪb/",
"tags": [
"General-American"
]
},
{
"ipa": "[-ɾə-]",
"tags": [
"General-American"
]
},
{
"audio": "En-us-binimetinib.oga",
"mp3_url": "https://upload.wikimedia.org/wikipedia/commons/transcoded/4/4d/En-us-binimetinib.oga/En-us-binimetinib.oga.mp3",
"ogg_url": "https://upload.wikimedia.org/wikipedia/commons/4/4d/En-us-binimetinib.oga",
"tags": [
"General-American"
],
"text": "Audio (GA)"
}
],
"word": "binimetinib"
}
{
"etymology_templates": [
{
"args": {
"1": "prefix"
},
"expansion": "prefix",
"name": "glossary"
},
{
"args": {
"1": "suffix"
},
"expansion": "suffix",
"name": "glossary"
},
{
"args": {
"1": "en",
"2": "",
"3": "-metinib",
"alt1": "bini-",
"pos1": "a unique prefix",
"pos2": "suffix indicating an inhibitor of mitogen-activated protein kinase kinase (MEK)"
},
"expansion": "bini- (a unique prefix) + -metinib (suffix indicating an inhibitor of mitogen-activated protein kinase kinase (MEK))",
"name": "affix"
}
],
"etymology_text": "From bini- (a unique prefix) + -metinib (suffix indicating an inhibitor of mitogen-activated protein kinase kinase (MEK)).",
"head_templates": [
{
"args": {
"1": "-"
},
"expansion": "binimetinib (uncountable)",
"name": "en-noun"
}
],
"hyphenation": [
"bi‧ni‧me‧ti‧nib"
],
"lang": "English",
"lang_code": "en",
"pos": "noun",
"senses": [
{
"categories": [
"English 5-syllable words",
"English entries with incorrect language header",
"English entries with language name categories using raw markup",
"English lemmas",
"English nouns",
"English terms suffixed with -metinib",
"English terms suffixed with -tinib",
"English terms with IPA pronunciation",
"English terms with audio links",
"English terms with quotations",
"English uncountable nouns",
"en:Pharmaceutical drugs"
],
"examples": [
{
"ref": "2017 February 28, Johanna C. Bendell et al., “A Phase 1 Dose-escalation and Expansion Study of Binimetinib (MEK162), a Potent and Selective Oral MEK1/2 Inhibitor”, in British Journal of Cancer, volume 116, Edinburgh: Nature Research, →DOI, →ISSN, →OCLC, page 576, column 1",
"text": "Binimetinib (MEK162; ARRY-438162) is a potent, adenosine triphosphate-uncompetitive, highly selective allosteric inhibitor of MEK1/2 with demonstrated on-target activity in vitro and in vivo, including models of cancer [...] In vivo, binimetinib displays broad anti-tumour activity in xenograft models derived from melanoma, colorectal cancer, non-small cell lung cancer (NSCLC), fibrosarcoma, cholangiocarcinoma, and pancreatic cancer. These non-clinical data support the use of binimetinib in a wide variety of tumour types, with a priority in tumours with aberrantly activated MAPK pathway signalling.",
"type": "quotation"
},
{
"ref": "2017 April 1, Reinhard Dummer et al., “Binimetinib versus Dacarbazine in Patients with Advanced NRAS-mutant Melanoma (NEMO): A Multicentre, Open-label, Randomised, Phase 3 Trial”, in David Collingridge, editor, The Lancet Oncology, volume 18, number 4, London: Lancet Publishing Group, →DOI, →ISSN, →OCLC, pages 435–445",
"text": "Binimetinib improved progression-free survival compared with dacarbazine and was tolerable. Binimetinib might represent a new treatment option for patients with NRAS-mutant melanoma after failure of immunotherapy.",
"type": "quotation"
},
{
"ref": "2018, Laurence Brunton, Bjorn Knollman, Randa Hilal-Dandan, Goodman and Gilman’s The Pharmacological Basis of Therapeutics, 13th edition, New York, N.Y.: McGraw Hill Professional, page 1212",
"text": "Under development are binimetinib, a MEK inhibitor being studied in patients with NRAS-mutant melanoma, and encorafinib, a BRAF inhibitor being used in combination with binimetinib for patients with BRAF-mutant melanoma.",
"type": "quotation"
},
{
"ref": "2018, Shane Y. Morita et al., Textbook of General Surgical Oncology, New York, N.Y.: McGraw Hill Professional, page 187",
"text": "The initial report of the phase I/II combination trial of encorafenib and binimetinib reported on 9 BRAF inhibitor naive and 14 BRAF inhibitor pretreated patients with metastatic BRAF mutant melanoma across a range of doses.",
"type": "quotation"
},
{
"ref": "2019 July 20, Heidi Finnes, “Binimetinib (Mektovi®)”, in Oncology Times: The Newspaper for Specialists in Cancer, volume 41, number 14, Philadelphia, Pa.: Lippincott Williams & Wilkins, →DOI, →ISSN, →OCLC, page 8",
"text": "Binimetinib is an oral reversible inhibitor of mitogen-activated extracellular signal-regulated kinase (MEK) 1/2. [...] Binimetinib inhibits MEK 1/2 downstream from BRAF and halts cancer cell signaling and survival. [...] Binimetinib is approved in combination with encorafenib, a BRAF inhibitor, for the treatment of unresectable or metastatic melanoma with a BRAF V600E/K mutation, as detected by an FDA-approved test.",
"type": "quotation"
},
{
"ref": "2020, Edward Chu, Vincent T[heodore] DeVita, Jr., “Chemotherapeutic and Biologic Drugs”, in Physicians’ Cancer Chemotherapy Drug Manual 2021, Burlington, Mass.: Jones & Bartlett Learning, →ISSN, page 77",
"text": "Special Considerations [...] 7. Monitor patients for an increased risk of new primary cancers, both cutaneous and non-cutaneous, while on therapy and for up to 6 months following the last dose of binimetinib. [...] 10. Baseline and periodic CPK levels while on therapy, as rhabdomyolysis has been observed with binimetinib therapy.",
"type": "quotation"
},
{
"ref": "2020, Gail M. Wilkes, Margaret Barton-Burke, “Molecular Targeted Therapy”, in Oncology Nursing Drug Handbook 2020–2021, Burlington, Mass.: Jones & Bartlett Learning, →ISSN, page 548",
"text": "Binimetinib is given in combination with encorafenib as each drug targets a different kinase in the RAS/RAF/MEK/ERK pathway to stop malignant cell proliferation and to tell the cells to die (undergo apoptosis). [...] Terminal half-life of binimetinib is 3.5 hours. [...] No clinically significant changes in binimetinib exposure were seen in patients with severe renal impairment.",
"type": "quotation"
}
],
"glosses": [
"A drug with the molecular formula C₁₇H₁₅BrF₂N₄O₃ that inhibits mitogen-activated protein kinase kinase (MEK), and is approved for use in combination with encorafenib to treat certain melanomas."
],
"links": [
[
"pharmacology",
"pharmacology"
],
[
"drug",
"drug#Noun"
],
[
"molecular formula",
"molecular formula"
],
[
"inhibit",
"inhibit"
],
[
"mitogen-activated protein kinase kinase",
"mitogen-activated protein kinase kinase"
],
[
"MEK",
"MEK"
],
[
"approve",
"approve"
],
[
"use",
"use#Noun"
],
[
"combination",
"combination"
],
[
"encorafenib",
"encorafenib"
],
[
"treat",
"treat#Verb"
],
[
"melanoma",
"melanoma"
]
],
"raw_glosses": [
"(pharmacology) A drug with the molecular formula C₁₇H₁₅BrF₂N₄O₃ that inhibits mitogen-activated protein kinase kinase (MEK), and is approved for use in combination with encorafenib to treat certain melanomas."
],
"tags": [
"uncountable"
],
"topics": [
"medicine",
"pharmacology",
"sciences"
]
}
],
"sounds": [
{
"ipa": "/bɪnɪˈmɛtɪnɪb/",
"tags": [
"Received-Pronunciation"
]
},
{
"ipa": "/bɪnɪˈmɛtɪnɪb/",
"tags": [
"General-American"
]
},
{
"ipa": "[-ɾə-]",
"tags": [
"General-American"
]
},
{
"audio": "En-us-binimetinib.oga",
"mp3_url": "https://upload.wikimedia.org/wikipedia/commons/transcoded/4/4d/En-us-binimetinib.oga/En-us-binimetinib.oga.mp3",
"ogg_url": "https://upload.wikimedia.org/wikipedia/commons/4/4d/En-us-binimetinib.oga",
"tags": [
"General-American"
],
"text": "Audio (GA)"
}
],
"translations": [
{
"code": "he",
"lang": "Hebrew",
"sense": "drug that inhibits mitogen-activated protein kinase kinase",
"word": "בינימטיניב"
},
{
"code": "ja",
"lang": "Japanese",
"sense": "drug that inhibits mitogen-activated protein kinase kinase",
"word": "ビニメチニブ"
},
{
"code": "sh",
"lang": "Serbo-Croatian",
"sense": "drug that inhibits mitogen-activated protein kinase kinase",
"tags": [
"Roman",
"masculine"
],
"word": "binimetinib"
}
],
"word": "binimetinib"
}
This page is a part of the kaikki.org machine-readable All languages combined dictionary. This dictionary is based on structured data extracted on 2024-05-20 from the enwiktionary dump dated 2024-05-02 using wiktextract (1d5a7d1 and 304864d). The data shown on this site has been post-processed and various details (e.g., extra categories) removed, some information disambiguated, and additional data merged from other sources. See the raw data download page for the unprocessed wiktextract data.
If you use this data in academic research, please cite Tatu Ylonen: Wiktextract: Wiktionary as Machine-Readable Structured Data, Proceedings of the 13th Conference on Language Resources and Evaluation (LREC), pp. 1317-1325, Marseille, 20-25 June 2022. Linking to the relevant page(s) under https://kaikki.org would also be greatly appreciated.